{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:44:12Z","timestamp":1790405052110,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Carevive Systems, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00520-024-08985-3","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T09:23:40Z","timestamp":1731921820000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Symptom experience of patients undergoing treatment for multiple myeloma: a longitudinal real-world electronic patient-reported outcomes study"],"prefix":"10.1007","volume":"32","author":[{"given":"Mihir N.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneli","family":"Nina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Branchaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris W.","family":"Herring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"8985_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73: 17-48","DOI":"10.3322\/caac.21763"},{"key":"8985_CR2","doi-asserted-by":"crossref","unstructured":"Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, Kota V, Ajebo GH (2021) Epidemiology, staging, and management of multiple myeloma. Med Sci (Basel) 9:3","DOI":"10.3390\/medsci9010003"},{"key":"8985_CR3","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516\u20132520","journal-title":"Blood"},{"key":"8985_CR4","doi-asserted-by":"crossref","unstructured":"Kristinsson SY, Anderson WF, Landgren O (2014) Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia 28: 1346\u20131348","DOI":"10.1038\/leu.2014.23"},{"key":"8985_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","volume":"83","author":"AT Johnsen","year":"2009","unstructured":"Johnsen AT, Tholstrup D, Petersen MA, Pedersen L, Groenvold M (2009) Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol 83:139\u2013148","journal-title":"Eur J Haematol"},{"key":"8985_CR6","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/cncr.29119","volume":"121","author":"EE Kent","year":"2015","unstructured":"Kent EE, Ambs A, Mitchell SA, Clauser SB, Smith AW, Hays RD (2015) Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage. Cancer 121:758\u2013765","journal-title":"Cancer"},{"key":"8985_CR7","doi-asserted-by":"crossref","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F, Anderson KC (2017) Multiple myeloma. Nat Rev Dis Primers 3: 17046","DOI":"10.1038\/nrdp.2017.46"},{"key":"8985_CR8","doi-asserted-by":"crossref","unstructured":"McCullough KB, Hobbs MA, Abeykoon JP, Kapoor P (2018) Common adverse effects of novel therapies for multiple myeloma (MM) and their management strategies. Curr Hematol Malig Rep 13:114\u2013124","DOI":"10.1007\/s11899-018-0443-0"},{"key":"8985_CR9","doi-asserted-by":"crossref","unstructured":"Pozzi S, Bari A, Pecherstorfer M, Vallet S (2021) Management of adverse events and supportive therapy in relapsed\/refractory multiple myeloma. Cancers (Basel) 13:4978","DOI":"10.3390\/cancers13194978"},{"key":"8985_CR10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.4065\/79.7.867","volume":"79","author":"SK Kumar","year":"2004","unstructured":"Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Larson DR, Kyle RA, Greipp PR (2004) Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 79:867\u2013874","journal-title":"Mayo Clin Proc"},{"key":"8985_CR11","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/17474086.2020.1800451","volume":"13","author":"AS Bruno","year":"2020","unstructured":"Bruno AS, Willson JL, Opalinska JM, Nelson JJ, Lunacsek OE, Stafkey-Mailey DR, Willey JP (2020) Recent real-world treatment patterns and outcomes in US patients with relapsed\/refractory multiple myeloma Expert. Rev Hematol 13:1017\u20131025","journal-title":"Rev Hematol"},{"key":"8985_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1080\/10428194.2022.2140284","volume":"64","author":"PF Wang","year":"2023","unstructured":"Wang PF, Yee CW, Gorsh B, Zichlin ML, Paka P, Bhak RH, Boytsov N, Khanal A, Noman A, DerSarkissian M, Ferrante S, Duh MS (2023) Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study. Leuk Lymphoma 64:398\u2013406","journal-title":"Leuk Lymphoma"},{"key":"8985_CR13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Raab MS, Schoen P, Cavo M (2016) Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 175:252\u2013264","journal-title":"Br J Haematol"},{"key":"8985_CR14","doi-asserted-by":"crossref","unstructured":"Kamal M, Wang XS, Shi Q, Zyczynski TM, Davis C, Williams LA, Lin HK, Garcia-Gonzalez A, Cleeland CS, Orlowski R (2021) Symptom burden and its functional impact in patients with \"symptomatic\" relapsed or refractory multiple myeloma. Support Care Cancer 29: 467\u2013475","DOI":"10.1007\/s00520-020-05493-y"},{"key":"8985_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","volume":"16","author":"C Ramsenthaler","year":"2016","unstructured":"Ramsenthaler C, Osborne TR, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ (2016) The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer 16:427","journal-title":"BMC Cancer"},{"key":"8985_CR16","doi-asserted-by":"crossref","unstructured":"Boland E, Eiser C, Ezaydi Y, Greenfield DM, Ahmedzai SH, Snowden JA (2013) Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. J Pain Symptom Manage 46: 671\u2013680","DOI":"10.1016\/j.jpainsymman.2012.11.003"},{"key":"8985_CR17","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.2217\/fon-2022-0378","volume":"18","author":"L Batchelder","year":"2022","unstructured":"Batchelder L, Philpott S, Divino V, Boytsov N, Maiese EM, Hogea C, Buckingham T, Chen CC, Rodriguez AM (2022) Physician treatment preferences for relapsed\/refractory multiple myeloma: a discrete choice experiment. Future Oncol 18:2843\u20132856","journal-title":"Future Oncol"},{"key":"8985_CR18","doi-asserted-by":"crossref","unstructured":"Sandhu S, King Z, Wong M, Bissell S, Sperling J, Gray M, Ratliff W, Herring K, LeBlanc TW (2020) Implementation of electronic patient-reported outcomes in routine cancer care at an academic center: identifying opportunities and challenges. JCO Oncol Pract 16: e1255-e1263","DOI":"10.1200\/OP.20.00357"},{"key":"8985_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00520-023-07836-x","volume":"31","author":"A Ribbands","year":"2023","unstructured":"Ribbands A, Boytsov N, Bailey A, Gorsh B, Luke E, Lambert A (2023) Real-world patient-reported outcomes and concordance between patient and physician reporting of side effects across lines of therapy in multiple myeloma within the USA. Support Care Cancer 31:371","journal-title":"Support Care Cancer"},{"key":"8985_CR20","doi-asserted-by":"crossref","unstructured":"LeBlanc MR, Hirschey R, Leak Bryant A, LeBlanc TW, Smith SK (2020) How are patient-reported outcomes and symptoms being measured in adults with relapsed\/refractory multiple myeloma? A systematic review. Qual Life Res 29: 1419-1431","DOI":"10.1007\/s11136-019-02392-6"},{"key":"8985_CR21","doi-asserted-by":"crossref","unstructured":"Pritchett JC, Patt D, Thanarajasingam G, Schuster A, Snyder C (2023) Patient-reported outcomes, digital health, and the quest to improve health equity. Am Soc Clin Oncol Educ Book 43:e390678","DOI":"10.1200\/EDBK_390678"},{"key":"8985_CR22","doi-asserted-by":"crossref","unstructured":"Geerts P, Eijsink J, Moser A, Ter Horst P, Boersma C, Postma M (2023) Rationale and development of an e-health application to deliver patient-centered care during treatment for recently diagnosed multiple myeloma patients: pilot study of the MM E-coach. Pilot Feasibility Stud 9:85","DOI":"10.1186\/s40814-023-01307-0"},{"key":"8985_CR23","doi-asserted-by":"crossref","unstructured":"Biran N, Anthony Kouyate R, Yucel E, McGovern GE, Schoenthaler AM, Durling OG, Unawane R, Schutt A, Panjabi S (2020) Adaptation and evaluation of a symptom-monitoring digital health intervention for patients with relapsed and refractory multiple myeloma: pilot mixed-methods implementation study. JMIR Form Res 4: e18982","DOI":"10.2196\/18982"},{"key":"8985_CR24","doi-asserted-by":"publisher","DOI":"10.2196\/46017","volume":"25","author":"J Lehmann","year":"2023","unstructured":"Lehmann J, de Ligt KM, Tipelius S, Giesinger JM, Sztankay M, Voigt S, van de Poll-Franse LV, Rumpold G, Weger R, Willenbacher E, Willenbacher W, Holzner B (2023) Adherence to patient-reported symptom monitoring and subsequent clinical interventions for patients with multiple myeloma in outpatient care: longitudinal observational study. J Med Internet Res 25:e46017","journal-title":"J Med Internet Res"},{"key":"8985_CR25","doi-asserted-by":"crossref","unstructured":"Lehmann J, Buhl P, Giesinger JM, Wintner LM, Sztankay M, Neppl L, Willenbacher W, Weger R, Weyrer W, Rumpold G, Holzner B (2021) Using the Computer-based Health Evaluation System (CHES) to support self-management of symptoms and functional health: evaluation of hematological patient use of a web-based patient portal. J Med Internet Res 23: e26022","DOI":"10.2196\/26022"},{"key":"8985_CR26","doi-asserted-by":"crossref","unstructured":"Wujcik D, Dudley WN, Dudley M, Gupta V, Brant J (2022) Electronic patient symptom management program to support patients receiving cancer treatment at home during the COVID-19 pandemic. Value Health 25: 931\u2013936","DOI":"10.1016\/j.jval.2022.01.023"},{"key":"8985_CR27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1188\/19.ONF.715-726","volume":"46","author":"JM Brant","year":"2019","unstructured":"Brant JM, Hirschman KB, Keckler SL, Dudley WN, Stricker C (2019) Patient and provider use of electronic care plans generated from patient-reported outcomes. Oncol Nurs Forum 46:715\u2013726","journal-title":"Oncol Nurs Forum"},{"key":"8985_CR28","doi-asserted-by":"crossref","unstructured":"Caston NE, Franks JA, Balas N, Eltoum N, Thigpen H, Patterson M, Azuero A, Ojesina AI, Dent DN, Hildreth K, Lalor FR, McGowen C, Huang CS, Dionne-Odom JN, Weiner BJ, Jackson BE, Basch EM, Stover AM, Howell D, Pierce JY, Rocque GB (2023) Evaluating nurses' time to response by severity and cancer stage in a remote symptom monitoring program for patients with breast cancer. JCO Clin Cancer Inform 7: e2300015","DOI":"10.1200\/CCI.23.00015"},{"key":"8985_CR29","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.1182\/blood-2023-180887","volume":"142","author":"NC Coombs","year":"2023","unstructured":"Coombs NC, Beamon E, Rusli E, Wujcik D, Galaznik A, Jamy O (2023) Exploring symptom burden, treatment bother, physical function, and quality of life by frailty status in patients with acute myeloid leukemia. Blood 142:5105\u20135105","journal-title":"Blood"},{"key":"8985_CR30","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1182\/blood-2015-05-647636","volume":"126","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar SV, Richardson P, San Miguel JF (2015) Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood 126:921\u2013922","journal-title":"Blood"},{"key":"8985_CR31","doi-asserted-by":"crossref","unstructured":"O'Donnell EK, Shapiro YN, Yee AJ, Nadeem O, Hu BY, Laubach JP, Branagan AR, Anderson KC, Mo CC, Munshi NC, Ghobrial IM, Sperling AS, Agyemang EA, Burke JN, Harrington CC, Richardson PG, Raje NS, El-Jawahri A (2022) Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer 128: 1996\u20132004","DOI":"10.1002\/cncr.34134"},{"key":"8985_CR32","doi-asserted-by":"crossref","unstructured":"Reeve BB, Mitchell SA, Dueck AC, Basch E, Cella D, Reilly CM, Minasian LM, Denicoff AM, O'Mara AM, Fisch MJ, Chauhan C, Aaronson NK, Coens C, Bruner DW (2014) Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst 106","DOI":"10.1093\/jnci\/dju129"},{"key":"8985_CR33","doi-asserted-by":"crossref","unstructured":"Minasian LM, O'Mara A, Mitchell SA (2022) Clinician and patient reporting of symptomatic adverse events in cancer clinical trials: using CTCAE and PRO-CTCAE((R)) to provide two distinct and complementary perspectives. Patient Relat Outcome Meas 13: 249\u2013258","DOI":"10.2147\/PROM.S256567"},{"key":"8985_CR34","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1007\/s00520-022-06802-3","volume":"30","author":"P Griffiths","year":"2022","unstructured":"Griffiths P, Peipert JD, Leith A, Rider A, Morgan L, Cella D, Cocks K (2022) Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients. Support Care Cancer 30:3613\u20133623","journal-title":"Support Care Cancer"},{"key":"8985_CR35","doi-asserted-by":"crossref","unstructured":"Ownby KK (2019) Use of the distress thermometer in clinical practice. J Adv Pract Oncol 10: 175-179","DOI":"10.6004\/jadpro.2019.10.2.7"},{"key":"8985_CR36","doi-asserted-by":"crossref","unstructured":"McInturf G, Younger K, Sanchez C, Walde C, Abdallah AO, Ahmed N, Shune L, Sborov DW, Godara A, McClune B, Sinclair CT, Mohyuddin GR (2022) Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. Eur J Haematol 109: 559\u2013565","DOI":"10.1111\/ejh.13843"},{"key":"8985_CR37","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/ejh.12790","volume":"97","author":"C Ramsenthaler","year":"2016","unstructured":"Ramsenthaler C, Kane P, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ (2016) Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol 97:416\u2013429","journal-title":"Eur J Haematol"},{"key":"8985_CR38","doi-asserted-by":"crossref","unstructured":"Mols F, Oerlemans S, Vos AH, Koster A, Verelst S, Sonneveld P, van de Poll-Franse LV (2012) Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry. Eur J Haematol 89: 311\u2013319","DOI":"10.1111\/j.1600-0609.2012.01831.x"},{"key":"8985_CR39","doi-asserted-by":"crossref","unstructured":"Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N, Kyriakou C, Williams CD, Peters S, Davies FE (2014) Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer 22: 417\u2013426","DOI":"10.1007\/s00520-013-1991-4"},{"key":"8985_CR40","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1186\/s12885-023-11115-7","volume":"23","author":"M Gunther","year":"2023","unstructured":"Gunther M, Hentschel L, Schuler M, Muller T, Schutte K, Ko YD, Schmidt-Wolf I, Jaehde U (2023) Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers. BMC Cancer 23:629","journal-title":"BMC Cancer"},{"key":"8985_CR41","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Ihorst G, Singh M, Rieth A, Saba G, Pellan M, Lebioda A (2021) Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany. Clin Lymphoma Myeloma Leuk 21: e160-e175","DOI":"10.1016\/j.clml.2020.10.002"},{"key":"8985_CR42","doi-asserted-by":"crossref","unstructured":"Omlin A, Blum D, Wierecky J, Haile SR, Ottery FD, Strasser F (2013) Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case-control study. J Cachexia Sarcopenia Muscle 4: 55\u201361","DOI":"10.1007\/s13539-012-0099-x"},{"key":"8985_CR43","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00520-023-07759-7","volume":"31","author":"L Zeng","year":"2023","unstructured":"Zeng L, Huang H, Liu Y, Ruan C, Fan S, Xia Y, Zhou J (2023) The core symptom in multiple myeloma patients undergoing chemotherapy: a network analysis. Support Care Cancer 31:297","journal-title":"Support Care Cancer"},{"key":"8985_CR44","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.6004\/jnccn.2020.7561","volume":"18","author":"AK Zaleta","year":"2020","unstructured":"Zaleta AK, Miller MF, Olson JS, Yuen EYN, LeBlanc TW, Cole CE, McManus S, Buzaglo JS (2020) Symptom burden, perceived control, and quality of life among patients living with multiple myeloma. J Natl Compr Canc Netw 18:1087\u20131095","journal-title":"J Natl Compr Canc Netw"},{"key":"8985_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ejh.12882","volume":"99","author":"LK Nielsen","year":"2017","unstructured":"Nielsen LK, Jarden M, Andersen CL, Frederiksen H, Abildgaard N (2017) A systematic review of health-related quality of life in longitudinal studies of myeloma patients. Eur J Haematol 99:3\u201317","journal-title":"Eur J Haematol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08985-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08985-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08985-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T15:05:57Z","timestamp":1733756757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08985-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["8985"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08985-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"16 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki. This study utilized a prospectively collected database of electronic patient-reported outcomes; we obtained approval from the Institutional Review Board at Duke University Medical Center for analysis of these data (Pro00108428).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Mihir N. Patel has received royalties from Prepped Health (Agreement #012617, HOPE). Suzanne Johnson and Julie Scott are employees of and hold stock or stock options in Carevive Systems, Inc. Thomas W. LeBlanc has received honoraria for consulting\/advisory boards from AbbVie, Agilix, Agios\/Servier, Apellis, Astellas, AstraZeneca, Beigene, BlueNote, BMS\/Celgene, Genentech, GSK, Lilly, Meter Health, Novartis, and Pfizer; speaking related honoraria from AbbVie, Agios, Astellas, BMS\/Celgene, GSK, Incyte, and Rigel; equity interest in Dosentrx and ThymeCare (stock options in a privately-held company); royalties from UpToDate; research funding from AbbVie, American Cancer Society, AstraZeneca, BMS, Deverra Therapeutics, Duke University, GSK, Jazz Pharmaceuticals, the Leukemia and Lymphoma Society, the National Institute of Nursing Research\/ National Institutes of Health, and Seattle Genetics. All other authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"802"}}